title: A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
abstract: Antigen-specific immunotherapy was studied in a multi-institutional phase 1/2 study by combining decitabine (DAC) followed by an autologous dendritic cell (DC)/MAGE-A1, MAGE-A3 and NY-ESO-1 peptide vaccine in children with relapsed/refractory solid tumors. Patients aged 2.5-15 years with relapsed neuroblastoma, Ewing's sarcoma, osteosarcoma and rhabdomyosarcoma were eligible to receive DAC followed by DC pulsed with overlapping peptides derived from full-length MAGE-A1, MAGE-A3 and NY-ESO-1. The primary endpoints were to assess the feasibility and tolerability of this regimen. Each of four cycles consisted of week 1: DAC 10 mg/m(2)/day for 5 days and weeks 2 and 3: DC vaccine once weekly. Fifteen patients were enrolled in the study, of which 10 were evaluable. Generation of DC was highly feasible for all enrolled patients. The treatment regimen was generally well tolerated, with the major toxicity being DAC-related myelosuppression in 5/10 patients. Six of nine patients developed a response to MAGE-A1, MAGE-A3 or NY-ESO-1 peptides post-vaccine. Due to limitations in number of cells available for analysis, controls infected with a virus encoding relevant genes have not been performed. Objective responses were documented in 1/10 patients who had a complete response. Of the two patients who had no evidence of disease at the time of treatment, one remains disease-free 2 years post-therapy, while the other experienced a relapse 10 months post-therapy. The chemoimmunotherapy approach using DAC/DC-CT vaccine is feasible, well tolerated and results in antitumor activity in some patients. Future trials to maximize the likelihood of T cell responses post-vaccine are warranted.
authors.affiliation: Department of Pediatrics, Hematology/Oncology, University of Louisville, 571 South Floyd Street, Suite 445, Louisville, KY, 40202, USA.
authors.forename: Deepa K
authors.initials: DK
authors.lastname: Krishnadas
authors.forename: Suzanne
authors.initials: S
authors.lastname: Shusterman
authors.forename: Fanqi
authors.initials: F
authors.lastname: Bai
authors.forename: Lisa
authors.initials: L
authors.lastname: Diller
authors.forename: Janice E
authors.initials: JE
authors.lastname: Sullivan
authors.forename: Alexandra C
authors.initials: AC
authors.lastname: Cheerva
authors.forename: Rani E
authors.initials: RE
authors.lastname: George
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Lucas
mesh_terms: D000293:Adolescent; D000951:Antigens, Neoplasm / Q000276:immunology; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019496:Cancer Vaccines / Q000008:administration & dosage*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D000077209:Decitabine; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D058950:Melanoma-Specific Antigens / Q000276:immunology; D008565:Membrane Proteins / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology; D009447:Neuroblastoma / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology; D012008:Recurrence; D012509:Sarcoma; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; C072011:MAGEA1 protein, human; C072013:MAGEA3 protein, human; D058950:Melanoma-Specific Antigens; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D000077209:Decitabine; D001374:Azacitidine